AptaBio Therapeutics Inc (293780) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.061x

Based on the latest financial reports, AptaBio Therapeutics Inc (293780) has a cash flow conversion efficiency ratio of -0.061x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-2.73 Billion ≈ $-1.85 Million USD) by net assets (₩44.61 Billion ≈ $30.23 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Check 293780 strategic asset allocation to assess the company's strategic physical and investment asset allocation.

AptaBio Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2024)

This chart illustrates how AptaBio Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. See shareholders equity of AptaBio Therapeutics Inc for net asset value and shareholders' equity analysis.

AptaBio Therapeutics Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of AptaBio Therapeutics Inc ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Energoaqua a.s. PR:ENRGA	N/A
Elite Naturel Organik Gida Sanayi ve Ticaret AS IS:ELITE	-0.007x
KOMPLETT ASA NK -40 F:GJ60	-0.308x
Mitrajaya Holdings Bhd KLSE:9571	0.097x
CAPRAL LTD. F:CBZ	N/A
John Hancock Investors Closed Fund NYSE:JHI	0.068x
Mostostal Zabrze - Holding SA WAR:MSZ	0.106x
Quantumsphere Acquisition Corporation NASDAQ:QUMS	-0.004x

Annual Cash Flow Conversion Efficiency for AptaBio Therapeutics Inc (2017–2024)

The table below shows the annual cash flow conversion efficiency of AptaBio Therapeutics Inc from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see AptaBio Therapeutics Inc market cap and net worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩54.20 Billion ≈ $36.73 Million	₩-12.16 Billion ≈ $-8.24 Million	-0.224x	+2.32%
2023-12-31	₩61.36 Billion ≈ $41.59 Million	₩-14.10 Billion ≈ $-9.55 Million	-0.230x	-76.05%
2022-12-31	₩52.37 Billion ≈ $35.49 Million	₩-6.83 Billion ≈ $-4.63 Million	-0.130x	+9.57%
2021-12-31	₩61.67 Billion ≈ $41.79 Million	₩-8.90 Billion ≈ $-6.03 Million	-0.144x	-174.59%
2020-12-31	₩72.04 Billion ≈ $48.82 Million	₩-3.79 Billion ≈ $-2.57 Million	-0.053x	+34.20%
2019-12-31	₩75.16 Billion ≈ $50.93 Million	₩-6.00 Billion ≈ $-4.07 Million	-0.080x	+16.38%
2018-12-31	₩18.31 Billion ≈ $12.41 Million	₩-1.75 Billion ≈ $-1.19 Million	-0.095x	-268.19%
2017-12-31	₩-31.54 Billion ≈ $-21.37 Million	₩-1.79 Billion ≈ $-1.21 Million	0.057x	--

About AptaBio Therapeutics Inc

KQ:293780 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$116.04 Million

₩171.23 Billion KRW

Market Cap Rank

#18720 Global

#915 in Korea

Share Price

₩6370.00

Change (1 day)

-3.19%

52-Week Range

₩6110.00 - ₩10440.00

All Time High

₩61500.00